Join

Compare · RTO vs TPVG

RTO vs TPVG

Side-by-side comparison of Rentokil Initial plc (RTO) and TriplePoint Venture Growth BDC Corp. (TPVG): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both RTO and TPVG operate in Other Consumer Services (Consumer Discretionary), so they compete in similar markets.
  • RTO is the larger of the two at $7.39B, about 32.9x TPVG ($224.9M).
  • Over the past year, RTO is up 23.3% and TPVG is down 23.8% - RTO leads by 47.1 points.
  • RTO has hit the wire 2 times in the past 4 weeks while TPVG has been quiet.
  • TPVG has more recent analyst coverage (19 ratings vs 12 for RTO).
PerformanceRTO+23.31%TPVG-23.83%
2025-06-03+0.00%2026-06-03
MetricRTOTPVG
Company
Rentokil Initial plc
TriplePoint Venture Growth BDC Corp.
Price
$29.13-0.63%
$5.38-2.89%
Market cap
$7.39B
$224.9M
1M return
-12.94%
-3.67%
1Y return
+23.31%
-23.83%
Industry
Other Consumer Services
Other Consumer Services
Exchange
NYSE
NYSE
IPO
2022
2014
News (4w)
2
0
Recent ratings
12
19
TPVG

TriplePoint Venture Growth BDC Corp.

TriplePoint Venture Growth BDC Corp is a business development company specializing investments in growth stage. It also provides debt financing to venture growth space companies which includes growth capital loans, equipment financings, revolving loans, and direct equity investments. The fund seeks to invest in e-commerce, entertainment, technology and life sciences sector. Within technology the areas of focus include: Security, wireless communication equipments, network system and software, business applications software, conferencing equipments/services .big data, cloud computing, data storage, electronics, energy efficiency, hardware, information services, internet and media, networking, semiconductors, software, software as a service, and other technology related subsectors and within life sciences the areas of focus include: biotechnology, bio fuels/bio mass, diagnostic testing and bioinformatics, drug delivery, drug discovery, healthcare information systems, healthcare services, medical, surgical and therapeutic devices, pharmaceuticals and other life science related subsectors. Within growth capital loans it invests between $5 million and $50 million, for equipment financings it invests between $5 million and $25 million, for revolving loans it invests between $1 million and $25 million, and for direct equity investments it may invest between $0.1 million and $5 million (generally not exceeding 5% of the company's total equity). The debt financing products are typically structured as lines of credit and it invests through warrants and secured loans. It does not take board seat in the company.